Back to News
Market Impact: 0.38
GSK strikes up to $750 million deal for cancer-targeting drug
Source: reuters.com
M&A & RestructuringHealthcare & BiotechPrivate Markets & Venture
GSK agreed to acquire a trispecific T-cell engager cancer drug from China-based Chimagen Biosciences in a deal worth up to $750 million. The transaction expands GSK's oncology pipeline through an immunotherapy designed to help T-cells target cancer, though deal terms beyond the maximum value were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
GSK0.62
More News
- OpenAI raises just $11bn of $30bn target as AI investor appetite cools
- Waymo’s backers valued it at $126 billion. The Alphabet division that houses it brought in $372 million last quarter—and lost $2.05 billion
- Nvidia weighs playing the cosigner for Nscale’s AI data center in West Virginia
- Illumina CEO on Q3 Results and Business Outlook
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors